JP2019525728A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525728A5
JP2019525728A5 JP2018557809A JP2018557809A JP2019525728A5 JP 2019525728 A5 JP2019525728 A5 JP 2019525728A5 JP 2018557809 A JP2018557809 A JP 2018557809A JP 2018557809 A JP2018557809 A JP 2018557809A JP 2019525728 A5 JP2019525728 A5 JP 2019525728A5
Authority
JP
Japan
Prior art keywords
seq
antibody
chain variable
variable region
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557809A
Other languages
English (en)
Japanese (ja)
Other versions
JP7194985B2 (ja
JP2019525728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/052545 external-priority patent/WO2017191561A1/en
Publication of JP2019525728A publication Critical patent/JP2019525728A/ja
Publication of JP2019525728A5 publication Critical patent/JP2019525728A5/ja
Application granted granted Critical
Publication of JP7194985B2 publication Critical patent/JP7194985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557809A 2016-05-02 2017-05-02 タウ認識抗体 Active JP7194985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330800P 2016-05-02 2016-05-02
US62/330,800 2016-05-02
PCT/IB2017/052545 WO2017191561A1 (en) 2016-05-02 2017-05-02 Antibodies recognizing tau

Publications (3)

Publication Number Publication Date
JP2019525728A JP2019525728A (ja) 2019-09-12
JP2019525728A5 true JP2019525728A5 (enExample) 2020-06-25
JP7194985B2 JP7194985B2 (ja) 2022-12-23

Family

ID=58709516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557809A Active JP7194985B2 (ja) 2016-05-02 2017-05-02 タウ認識抗体

Country Status (18)

Country Link
US (2) US10906964B2 (enExample)
EP (1) EP3452509A1 (enExample)
JP (1) JP7194985B2 (enExample)
KR (2) KR102750101B1 (enExample)
CN (1) CN109415434B (enExample)
AU (1) AU2017259039B2 (enExample)
BR (1) BR112018072394A2 (enExample)
CA (1) CA3022765A1 (enExample)
CO (1) CO2018012987A2 (enExample)
CU (1) CU24538B1 (enExample)
EA (1) EA201892412A1 (enExample)
MX (1) MX2018013386A (enExample)
MY (1) MY197413A (enExample)
PE (1) PE20190208A1 (enExample)
SA (1) SA518400354B1 (enExample)
SG (1) SG11201809331RA (enExample)
WO (1) WO2017191561A1 (enExample)
ZA (1) ZA201808043B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
EA202092088A1 (ru) 2018-03-05 2020-11-13 Янссен Фармацевтика Нв Антитела анти-phf-тау и их применение
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン
EP4192497A4 (en) 2020-08-07 2024-08-21 Othair Prothena Limited MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
JP2008520186A (ja) 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体
PL1820022T3 (pl) 2004-11-10 2009-11-30 Boehringer Ingelheim Pharma Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006074071A1 (en) 2004-12-30 2006-07-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Framework residue substituted humanized col-1 antibodies and their use
WO2006108234A1 (en) * 2005-04-13 2006-10-19 Garvan Institute Of Medical Research Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2007147213A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
JP5467415B2 (ja) 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ccr2에 대한 항체
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US20110009628A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
JP5697044B2 (ja) 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
AR090352A1 (es) 2012-03-28 2014-11-05 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
US9428864B2 (en) 2012-04-18 2016-08-30 E I Du Pont De Nemours And Company Multilayered sheet
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティWashington University タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A3 (en) 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20201422T1 (hr) * 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP3418430B1 (en) 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
HRP20210124T1 (hr) 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3359569A2 (en) 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
WO2018156250A1 (en) 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3877410A4 (en) 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CA3118818A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
CN113597431B (zh) 2019-02-08 2025-02-21 普罗塞纳生物科学有限公司 识别Tau的抗体
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体

Similar Documents

Publication Publication Date Title
JP2023113836A5 (enExample)
JP2020520231A5 (enExample)
IL262726B1 (en) Antibodies recognizing tau
JP2018506277A5 (enExample)
JP2023027258A (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2019525724A5 (enExample)
JP2023509196A5 (enExample)
JP2016512551A5 (enExample)
JP2021191763A5 (enExample)
JP2025029046A5 (enExample)
JP2020513791A5 (enExample)
JP2018510617A5 (enExample)
JP2015520758A5 (enExample)
JP2022506719A5 (enExample)
JP2018509889A5 (enExample)
JP2010532764A5 (enExample)
JP2008516970A5 (enExample)
JP2017526370A5 (enExample)
JP2019528083A5 (enExample)
JP2016536020A5 (enExample)
JP2011509245A5 (enExample)
JP2018502060A5 (enExample)
JP2020514277A5 (enExample)
JP2014039548A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1